NOVARTIS

Velocity Clinical Research appoints Renata Berardocco as Executive Vice President and Managing Director for Latin America, aiming to expand its global network and leverage her experience in multisite networks and patient recruitment.

Top pharmaceutical companies like Pfizer, Roche, Johnson & Johnson, Novartis, Merck, AstraZeneca, Sanofi, GSK, AbbVie, and Bayer lead in innovation, focusing on areas such as mRNA vaccines, cancer treatments, immunology, and gene therapy, shaping the future of healthcare through R&D investments and strategic pivots.

Georg Schett presented data on CD19-directed CAR-T therapies in refractory autoimmune and rheumatic diseases at ACR Convergence 2024, highlighting low relapse rates and faster manufacturing processes.

Global Immuno-Oncology Clinical Trials Market report analyzes current status, future trends, and growth, covering major players like ICON PLC, IQVIA Holdings Inc., Covance, BioNTech, and others. It provides historical, current, and forecast market size, segmentation, and regional analysis. Key factors influencing market dynamics, including drivers, restraints, and projections, are detailed. The report also offers insights into market shares, strategies, and emerging niche segments.

The hidradenitis suppurativa market is projected to grow at a CAGR of 12.4% by 2034, driven by increased awareness, treatment access, biologic therapy approvals, and a robust pipeline. The market size in the 7MM was USD 1.4 billion in 2023, with approximately 6.2 million prevalent cases. Key companies and treatments include Incyte Corporation, AbbVie, MoonLake Immunotherapeutics, and therapies like Povorcitinib, RINVOQ, Lutikizumab, and Sonelokimab. Regulatory milestones and clinical trials are advancing, with potential market shifts expected from emerging therapies.

FDA approves Bimzelx, the first interleukin-17F and -17A inhibitor, for moderate to severe hidradenitis suppurativa in adults, based on BE HEARD trials results.

The EC fined Teva €462.6 million for abusing its dominant position to delay competition to Copaxone, marking the first time a pharma company was held liable for 'exclusionary disparagement.' This decision highlights the rising tide of antitrust enforcement against disparagement practices in the pharma sector, raising questions about the boundary between legitimate competition and illegal means.

Novartis' NLRP3 inhibitor NVP-DFV890, with a sulfonimidamide motif, shows reduced hydrolysis and promising PK in humans. It advances in Ph. II trials for coronary heart disease and knee osteoarthritis, as presented by Angela Mackay at EFMC-ISMC 2024.

Schrödinger and Novartis announce a $2 billion+ collaboration to advance small molecule candidates, expanding Novartis' access to Schrödinger's computational predictive modeling technology. The deal includes $150 million upfront and potential milestone payments of up to $2.272 billion, with Schrödinger eligible for royalties on commercialized products.